🚨 🚨 Investors were pleased with Eli Lilly on Tuesday after the company assured them that it could overcome ongoing supply constraints for its popular drugs. Eli Lilly hiked its full-year guidance in part due to optimism around increased production of Zepbound, its diabetes injection Mounjaro and similar drugs for the rest of the year
Receive Real-Time Algo Generated trading alerts on WhatsApp with an Accuracy Ratio of 90%
Asset Classes: Global Stocks, FX, Exchange Traded Funds (ETFs), Futures and Crypto
Specialised Videos: Gain Access To Member-Only Financial Videos On Vimeo
AlgoTrader 